ELISA for Pulmonary Disease Biomarkers | BioVendor #11

In this presentation, I would like to give
you some information about ELISA kits in BioVendor portfolio, which are intended for assaying
pulmonary disease markers or more generally protein molecules somehow participating in
pathological processes that occur in lungs. BioVendor company has a long tradition in
the development of immunoassays as well as the development and production of antibodies
and recombinant proteins. Our ELISA kits for the determination of biomarkers
in various clinical fields have gained a solid reputation and were frequently referred in
top class scientific journals. Here you can see only short extract from ELISA kits that BioVendor offers from the field
of pulmonary disease. I will be speaking about only some of them
in detail – those marked with bold letters– which are more relevant in diagnosis and research
of pulmonary disease. Before I start with the first protein molecule, let me remind types of samples which are suitable
for pulmonary disease markers measurement. We can test, of course, serum or plasma samples,
or, there is a possibility to measure markers secreted in respiratory tract – so we can
use, for instance: sputum, bronchoalveolar lavage fluid or similar fluids. First protein molecule, we have selected for
you, is Club Cell Protein, also called CC16. It was formerly called also Clara cell protein. But, using this name was suggested to be stopped
few years ago. The German scientist who discovered and described
pulmonary club cells, where club cell protein is primarily produced, Max Clara, had been
a member of Nazi party and used tissue samples from executed prisoners during the Second
World War. Human club cell protein may be considered
as a marker of epithelial airway injury. One of the main functions of club cells is
to protect the bronchiolar epithelium. In this context, CC16 has been largely studied
especially in association with its protecting effects at cigarette smoke-induced inflammation
and injury and in chronic obstructive pulmonary disease (COPD). As you can see in the picture, active smokers
have significantly reduced serum levels of CC16 compared to non-smoker controls; COPD
patients (this group comprised only non-smokers) have even lower CC16 levels in serum than
smokers. Reduced levels of CC16 may mean also increased
risk of chronic bronchitis. And they are also associated with cystic fibrosis
pulmonary exacerbation. CC16 has been indicated as a potential therapeutic
target for COPD. Now, let us take two proteins together. These are surfactant proteins – A and D. They
form a principal part of the protein component in the lung surfactant and participate in
innate immunity response. SP-D serum levels are elevated in patients
with idiopathic pulmonary fibrosis (IPF) and associated also with increased mortality. SP-A might also serve as a predictor of mortality
in IPF. This protein is also potentially useful as
a biomarker which can help to differentiate among various forms of interstitial lung diseases. Both these proteins have been evaluated in
extensive meta-analysis using big number of studies as useful for differential diagnosis
and prediction of survival at IPF. SP-D is further supposed to be one of best
markers of COPD, especially in a combination with certain other markers. KL-6 is highly glycosylated protein, which
was first suggested as a tumour marker. Later, it appeared that it is inferior if
compared with some other cancer markers like carcinoembryonic antigen (CEA). KL-6 promotes migration, proliferation and
survival of lung fibroblasts. It was suggested as a diagnostic marker generally
for interstitial lung diseases, specifically as a diagnostic and prognostic marker for
idiopathic pulmonary fibrosis. Its increased levels might mean also increased
risk of idiopathic interstitial pneumonia and it was used as a diagnostic marker in
sarcoidosis. Further, connective tissue growth factor (CTGF)
is a fibrogenic marker for chronic fibrotic diseases. We can find increased CTGF concentrations
in blood and urine of patients with idiopathic pulmonary fibrosis and in blood of patients
with stable asthma. CTGF is a central mediator of tissue remodeling
and fibrosis, as is shown in the picture on right. It participates also in fibrotic processes
associated with radiation therapy at cancer treatment. That is why it might be necessary to monitor
CTGF concentration as a marker of these fibrotic processes. BioVendor offers also ELISA kits for determination
of some matrix metalloproteinases, namely three of them, MMP-7, MMP-8 and MMP-9. I put just a couple of general pieces of information
about these proteins. They are proteases with zinc-binding motif,
it means they have enzymatic activity due to which they are capable to degrade extracellular
matrix and this way to participate in tissue remodelling or maintenance. MMPs regulate release or activation of various
important molecules like cytokines, chemokines, hormones etc. They are associated with processes like immunity
response or inflammation. This list shows the discussed ELISA kits with
their respective catalogue numbers, from MMPs only MMP-8 is mentioned here. BioVendor can offer you also recombinant (prokaryotic
or eukaryotic) proteins concerning pulmonary disease research and/or diagnostics. In addition, we offer also some antibodies,
applicable in this field. I believe you have found something interesting
in my presentation also for your own work. But it was just a small starter from a wide
menu of BioVendor biomarker immunoassays. Visit us at the www.biovendor.com website
where it is quite easy to find an ELISA kit, protein, antibody or miRNA immunoassay meeting
your needs. Feel free to contact our product managers
and ask for help!

Leave a Reply

Your email address will not be published. Required fields are marked *